Examination of the validity of the 2022 guideline for the prevention of arteriosclerotic diseases from the viewpoint of the size of lipoprotein particles
Conditions
Interventions
A regular dose of rosuvastatin or atorvastatin is administered, blood tests are performed monthly or every few months at the outpatient department of our department, the dose is adjusted, and if neces
Sponsors
Saitama Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Outpatients of Saitama Medical University who have agreed to participate in this study and treatment according to the 2022 Arteriosclerotic Disease Prevention Guidelines, those who meet the following conditions. 1.Patients with 100 mg/dL or more in case of diabetes, peripheral arterial disease, microangiopathy (retinopathy, nephropathy, neuropathy), or smoking 2.Patients with diabetes not accompanied by 1. above 120 mg/dL 3.Patients with an LDL-C level of 70mg/dl or higher in the secondary prevention of arteriosclerotic disease prevention guidelines
Exclusion criteria
Exclusion criteria: 1) Patients receiving insulin 2) Patients receiving glucagon-like peptide 1 (GLP-1) receptor agonists 3) Male, serum Cr over 3.0 mg/dL, female, serum Cr over 2.5 mg/dL 4) Fasting triglyceride (TG) over 400mg/dL 5) HbA1c changed by 3% or more within 2 months 6) Severe ketosis, diabetic coma or precoma, peripheral artery disease, abdominal aortic aneurysm, carotid artery occlusion >50%, carotid endarterectomy, carotid artery stenting, renal artery stenosis, renal artery stenting a case with 7) Patients with severe infections and severe trauma before and after surgery 8) Women who are pregnant or breastfeeding 9) Women of childbearing potential without effective contraceptive methods 10) Patients judged by the investigator and physician to be inadequate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TC, TG, HDL-C, LDL-C, lipoprotein size, ability to miniaturize lipoprotein | — |
Secondary
| Measure | Time frame |
|---|---|
| apoA-I, apoE, apoB, creatinine, BUN, urinalysis, AST, ALT, CK, fasting blood glucose (diabetic cases), HbA1c (diabetic cases), apoE phenotype, blood pressure, weight, physical findings including interview, electrocardiogram, coronary artery computed tomography | — |
Countries
Japan
Contacts
Public ContactIkuo Inoue
Saitama Medical University Department of Endocrinology and Diabetes
Outcome results
None listed